Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Study to Assess the Long-Term Safety of Solriamfetol in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)

NCT07773883 is registered in ClinicalTrials.gov with Axsome Therapeutics, Inc. as lead sponsor.

NCT NCT07773883
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07773883 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Study to Assess the Long-Term Safety of Solriamfetol in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Lead sponsor
Axsome Therapeutics, Inc.
Phase
Phase 3
Overall status
Enrolling by invitation
Start date
August 6, 2026
Completion date
December 31, 2027
Enrollment
300 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

adhd